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Abstract
The majority of human high grade serous epithelial ovarian cancer (SEOC) is characterized by
frequent mutations in p53 and alterations in the RB and FOXM1 pathways. A subset of human
SEOC harbors a combination of germline and somatic mutations as well as epigenetic dysfunction
for BRCA1/2. Using Cre-conditional alleles and intrabursal induction by Cre-expressing
adenovirus in genetically engineered mice, we analyzed the roles of pathway perturbations in
epithelial ovarian cancer initiation and progression. Inactivation of RB-mediated tumor
suppression induced surface epithelial proliferation with progression to stage I carcinoma.
Additional biallelic inactivation and/or missense p53 mutation in the presence or absence of
Brca1/2 caused progression to stage IV disease. As in human SEOC, mice developed peritoneal
carcinomatosis, ascites, and distant metastases. Unbiased gene expression and metabolomic
profiling confirmed that Rb, p53, and Brca1/2-triple mutant tumors aligned with human SEOC,
and not with other intraperitoneal cancers. Together, our findings provide a novel resource for
evaluating disease etiology and biomarkers, therapeutic evaluation, and improved imaging
strategies in epithelial ovarian cancer.
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Ovarian cancer is the 5th deadliest disease among American women (1), with over 50%
presenting with serous papillary histology. High grade serous epithelial ovarian cancer
(SEOC) is associated with intraperitoneal spreading (carcinomatosis) and distant metastases.
Standard treatment is aggressive surgical resection followed by platinumtaxane
chemotherapy. Platinum-resistant cancer recurs in approximately 25% of patients within 6
months (2), and the overall five-year survival probability is 31% (3). Current methods for
early detection, such as transvaginal ultrasound and blood Cancer Antigen 125 (CA125)
levels have shown limited effectiveness (4, 5).
The Cancer Genome Atlas (TCGA) study of a large high grade SEOC cohort revealed that
mutations in TP53 predominated, occurring in at least 96% of tumors (6). Brca1 and Brca2
were mutated in 22% of tumors, representing a combination of germline and somatic
mutations (6). Known cancer-associated pathways such as RB1 and PI3K/RAS were
deregulated in 67% and 45% of cases, respectively (6).
Advances in modeling cancers in genetically engineered mice (GEM) have facilitated
mechanistic understanding of tumor development and applicability in preclinical studies for
several cancers [reviewed in (7-9)]. GEM models of endometrioid (10) and other epithelial
ovarian cancers (11-15) have been generated based on alterations of specific genetic
pathways. While two studies showed that concomitant inactivation of Brca1 and p53 or Rb1
and p53 in mouse ovarian surface epithelium (OSE) cells can give rise to carcinomas with
serous histology, respectively (11, 16), in two other studies ovary-specific conditional
inactivation of Brca1 and p53, in the presence or absence of Rb, resulted in ovarian
leiomyosarcomas (13, 15). Despite these extensive studies, the combination of pathway
perturbations leading to consistent initiation and progression of metastatic SEOC-like
disease in the mouse has been elusive. Here, we describe a comprehensive temporal study of
the most common pathways altered in human SEOC. Using selective induction of individual
or combinations of Brca1 or Brca2, p53 knockout and/or mutant alleles and Rb tumor
suppression (Rb-TS) inactivation, we analyzed the relative contribution to disease
progression from tumor initiation to invasive carcinomas with carcinomatosis and distant
metastases. Genome-wide expression, serum metabolomic and marker studies indicate that




All experimental animals were maintained in accordance with the Institutional Animal Care
and Use Committee (ACUC) and the NIH Guide for the Care and Use of Laboratory
Animals. All procedures performed on mice were approved by the ACUC of Frederick
National Laboratory for Cancer Research (FNLCR), Maryland. Brca1fl/fl [FVB;129-
Brca1tm2Brn], Brca2fl/fl [STOCK Brca2tm1Brn], p53fl/fl [FVB;129-Trp53tm1Brn] and p53LSL
R172H/+ [129S4-p53tm2Tyj] mice were obtained from the MMHCC Mouse Repository
(National Cancer Institute, Rockville, MD, USA). Conditional TgK18GT121tg/+ BAC
transgenic mice were generated by insertion of a floxed eGFP STOP T121 cassette several
base pairs upstream of the 1st ATG start codon in exon 1 of the Keratin 18 gene by
recombineering (17). Rosa26STOPfloxLacZ reporter mice [B6;129-Gt(ROSA)26SorTM1sor]
were purchased from the Jackson Laboratory.
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Recombinant adenovirus Ad5-CMV-Cre (Adeno-Cre) was purchased from the University of
Iowa Transfer Vector Core at a titre of 1011-1012 infectious particles/ml. To demonstrate our
capability to successfully perform intrabursal inductions, we performed intrabursal
injections of Adeno-Cre as previously described (11) on 7-8 week-old female
ROSA26STOPfloxPlacZ reporter mice. The right ovary was injected with approximately 7
μL of Adeno-Cre virus into the ovarian bursa near the oviducts during survival surgery 36
hours following super ovulation. Injected ROSA26STOPfloxPlacZ females were euthanized
2 weeks post injection, ovaries were removed and whole mounts stained for LacZ
expression (Supplementary Material and Methods).
Tissue collection, pathological and immunohistochemical analysis
Animals were euthanized by CO2 inhalation, ovaries and other affected organs were fixed in
10% neutral buffered formalin, processed for paraffin embedding and characterized by
microscopic evaluation. Five μm serial sections were cut for H&E and IHC. Pathological
evaluation of histological findings was performed by a board certified veterinary pathologist
(P. L. M.) according to existing human epithelial ovarian cancer classifications
[International Federation of Gynecology and Obstetrics (FIGO)].
Paraffin sections were deparaffinized in xylene, rehydrated in ethanol according to standard
protocol and subsequently used for IHC stains. Antibodies and conditions used for IHC
stains are listed in Supplementary Material and Methods. For all IHC stains 3,3′-
Diaminobenzidine (DAB) (Sigma) substrate was used to visualize peroxidase activity
followed by hematoxylin counterstain, dehydration and mounting.
Detailed procedures and primer sequences used for genotyping and detection of recombined
alleles, LacZ staining, MR imaging, microdissection and sequencing, metabolome profiling
and gene expression profiling can be found in Supplementary Materials and Methods.
Results
Conditional inactivation of RB tumor suppression in OSE causes stage I SEOC
Based on the frequency with which Rb is altered in human cancers, redundancy among the
pRb family proteins appears to be more widespread in the mouse than in the human. Indeed,
recent cancer genome studies indicate that several points in this pathway are altered, but in a
mutually exclusive pattern for individual tumors. The sum of these lesions indicates that
most human solid malignancies, including SEOC, are aberrant in RB-TS (18). Given the
limitation of allele combinations possible in the GEM experimental systems and the
redundancy in the pathway, we used an epithelial-specific Cre-dependent allele expressing
T121 to dominantly interfere with all three pocket proteins (pRB, p107 and p130), thus
facilitating RB-TS inactivation in vivo with a single allele (19, 20). T121 (the N-terminal
domain of SV40 T antigen) was directed to OSE using transgenic TgK18GT121 mice that
carry a bacterial artificial chromosome (BAC) containing the mouse cytokeratin (CK) 18
gene, into which a Cre-conditional loxP-GFP-stop-loxP (LSL) T121 cassette was inserted
(Fig. 1A) (17). To selectively induce T121 in OSE, adenoviral Cre (Adeno-Cre) was
introduced under the bursa (Suppl. Figure S1A a,b). Deletion efficiency was monitored by
IHC 3 months post induction (pi) for GFP (no deletion), T121 (deletion) and CK18 (cell
type) (Fig. 1A, B). GFP was detected diffusely in CK18 expressing OSE cells of the
uninjected and in some cells of the injected ovary (Fig. 1B a,b). T121 was present only in
OSE cells of the injected ovary (Fig. 1B c,d), indicating successful recombination within the
TgK18GT121 transgene. Mice were examined at various times pi. All uninjected ovaries
were normal up to 24 months pi (Fig. 1 B a,c,e). In contrast, 72 % (16/22) of injected
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TgK18GT121 ovaries had cytologic abonormalities in the OSE. Of these, 27% (6/22)
developed minimal to mild atypical hyperplasia with occasional papillary epithelial
projections 3 to 24 months pi. An additional 27% (6/22) of mice had OSE carcinoma in situ
(CIS) with no significant invasion into the underlying ovary or overlying bursa (5 and 24
months pi, Fig. 1C a,b, Fig. 2A). In 18% (4/22) of induced TgK18GT121 mice, the ovarian
tumors had progressed to SEOC pathology with early invasion into ovary and bursa (Fig.
1Cc,d; 2A). Histologically, tumors were characterized by high mitotic (>12 mitoses per ten
40× fields) and apoptotic rates (Fig. 1C c,d), consistent with the acute induction of these
outcomes in other cell types upon RB-TS inactivation (21). In summary, inactivation of RB-
TS was sufficient to cause OSE proliferation, with progression only to stage I disease (WT
vs TgK18GT121, Man Whitney test, p<0.0001).
Brca1/2 or p53 mutations/deletions alone or in combination fail to initiate OSE pathology
The current report of high frequency of TP53 mutations and involvement of Brca1 and
Brca2 aberrations in human SEOC patients (6) prompted us to examine roles for these
perturbations in mouse SEOC. Since p53 missense mutations have tissue and mutant-
specific functions that can differ from loss of protein (22),(23), we evaluated both
conditional inactivation (p53fl/fl) and missense mutation p53R172H expression using the
Adeno-Cre induction described above. The p53 DNA binding mutation R172H is analogous
to the R175H hotspot mutation frequently identified in human cancers, including ovarian
carcinomas (24). In addition, we generated mice with allele combinations in order to model
the frequent loss of the remaining wild-type p53 allele observed in human tumors.
Reproductive tracts and affected organs of all single and double combinations of Brca1,
Brca2 and p53 alleles were analyzed (Brca1fl/fl, Brca2fl/fl, p53R172H/+, p53fl/fl, p53R172H/fl,
Brca1fl/fl/p53R172H/+, Brca1fl/fl/p53R172H/fl, Brca1fl/fl/p53fl/fl, Brca2fl/fl/p53 R172H/+,
Brca2fl/fl/p53R172H/fl, Brca2fl/fl/p53fl/fl). None of the injected or un-injected ovaries from
these mice displayed pathological changes in the OSE up to 24 months pi (Figure 2B, Table
1). Brca1fl/fl and Brca2fl/fl mice developed non-ovarian neoplasms at a similar frequency as
wildtype mice (Suppl. Table 1). However, mice carrying the p53R172H allele, a null allele
before recombination, developed an increased frequency of lymphomas and sarcomas
consistent with the tumor spectrum of p53+/- mice (25) (Suppl. Table 1). The failure to elicit
OSE pathology alone or in combination indicates that perturbation of p53 and/or Brca1/2
cannot initiate and may instead progress disease.
Histopathological features of SEOC in Rb, p53 and Brca1/2 compound mice parallel human
disease
To model the concurrent dysregulation of RB-TS and p53 with or without Brca1 or Brca2
pathways, we generated mice carrying a range of allele combinations. The frequency of
SEOC pathology development among these animals varied as follows: 72%
TgK18GT121tg/+/p53R172H/fl, 88% TgK18GT121tg/+/p53fl/fl, 70% TgK18GT121tg/+/Brca1fl/fl/
p53R172H/fl, 68% TgK18GT121tg/+/Brca2fl/fl/p53R172H/fl and 78% TgK18GT121tg/+/
Brca1fl/fl/p53fl/fl (Table 1, Fig. 2C-E). Disease progression in these mice was staged in a
manner similar to the human ovarian carcinoma staging scheme (FIGO) (Fig. 2F, Suppl. Fig.
S1B,C) (26).
Ovarian tumor development could be followed by MRI and resulted in large palpable
masses on the injected ovary along with hemorrhagic or serous ascites (Fig. 3A-C). OSE
carcinomas showed a range of morphological patterns observed in SEOC of women,
including papillary, micropapillary/filigree, microcystic, poorly differentiated
adenocarcinoma and solid/undifferentiated (Fig. 3D-I). Multiple histological patterns were
frequently observed in the same tumor. The cytology was often high grade with prominent
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cellular/nuclear pleomorphism and >10 mitoses per 40× field. Similar to SEOC in humans,
the mice developed multifocal peritoneal carcinomatosis with tumor spread to all abdominal
organs (Fig. 3J). Distant metastases were also observed, and followed a pattern similar to
that reported in humans (27). Metastases were observed in the pleura of 87.5% (21/24) (Fig.
3K), in the lung of 83% (20/24) and in the liver of 46% (11/24) of mice with stage IV
disease (Fig. 3L).
In addition to pathological changes in the OSE, 2% (11/537) of mice had transformation of
the oviduct epithelium. The oviduct lesions ranged from atypical hyperplasia (4/11) to
carcinoma in-situ (3/11) to adenocarcinoma (4/11). In contrast to the OSE lesions which
primarily had a papillary morphology, the oviduct lesions were characterized by a glandular/
acinar histology (Fig. 4). Based on these significant histological differences, it is considered
unlikely that any of the carcinomatosis or metastasis arose from these oviduct
adenocarcinomas.
Immunohistochemical analysis confirmed that all SEOC, peritoneal and distant metastases
expressed T121 and CK18. Further immunophenotyping revealed expression of CA125 and
Wilms’ tumor 1 (WT1), markers typically expressed in human SEOC (28, 29), in OSE and
carcinoma cells (Suppl. Fig. S2A). Pax8 and Calretinin staining (Suppl. Fig. 2B) has been
used to differentiate between human SEOC (Calretinin−, Pax8+) and intraperitoneal
mesothelioma (Calretinin+, Pax8−) (30, 31). While normal murine OSE and most SEOCs
were Pax8 negative, 9% (2/22) SEOC and peritoneal carcinomatosis had rare (<1% of cells)
Pax8 expression (Fig. 4). In contrast, all of the oviduct adenocarcinomas had strong nuclear
Pax8 expression similar to the normal oviduct epithelium (Fig. 4a-f). To further distinguish
SEOC from intraperitoneal malignancies, such as diffuse malignant peritoneal mesothelioma
(DMPM), we determined the staining patterns for estrogen receptor (ER), progesterone
receptor (PR) and cytokeratins CK5 or CK6. As in human SEOCs (30, 32-35), normal
murine OSE and carcinoma cells as well as abdominal carcinomatosis and metastases were
strongly ER positive with rare expression of PR and did not express CK5 or CK6 (Fig. 4g-x,
Supplementary Material and Methods). In contrast, a human DMPM was CK5/CK6+, ER−
and PR− as expected (Fig. 4 f, l, r, x) (33-35). In summary, these mice develop tumors that
grossly, histologically and immunophenotypically resemble human SEOC.
Role of Brca1/2 and p53 in tumor progression
The overall penetrance of SEOC in compound mutants containing RB-TS, biallelic p53 with
or without Brca1/2 deletion was very similar (Table 1, Fig. 2E). The inactivation of Brca1
increased the incidence of stage III and IV SEOC from 8% in TgK18GT121tg/+/p53R172H/+
mice to 16% in TgK18GT121tg/+/Brca1fl/fl/p53R172H/+ mice (Table 1, Fig. 2E). However,
this increase did not reach statistical significance, possibly due to the fact that the Brca1 and
2 alleles are less efficiently rearranged compared to p53 and TgK18GT121 alleles (Suppl.
Fig. S3A-C). While it is possible that the deletion is inefficient, no progression was observed
in TgK18GT121tg/+/Brca1fl/fl compared to TgK18GT121tg/+ mice up to nearly 2 years pi
indicating that no deleted cells contributed to the tumor progression.
Induced TgK18GT121tg/+/p53R172H/+, TgK18GT121tg/+/Brca1fl/fl/p53R172H/+ and
TgK18GT121tg/+/Brca2fl/fl/p53R172H/+ mice carrying one mutant p53R172H allele developed
mainly low grade SEOC at a frequency between 21% and 42% (Table 1, Fig. 2C, D). In
contrast, compound mutant mice containing biallelic p53 modification (either p53R172H/fl or
p53fl/fl) presented with SEOC of all stages at an increased frequency of 68% to 88%,
respectively (Table 1, Fig. 2E) indicating that biallelic p53 perturbation is associated with
SEOC disease progression.
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Consistent with other studies, mutant P53R172H was not stably expressed in normal OSE or
carcinoma cells from induced TgK18GT121tg/+/p53R172H/+ mice as determined by IHC
(Suppl. Fig. S4A). However, strong P53 expression was detectable in SEOC from
TgK18GT121tg/+/p53R172H/fl mice indicating that an additional event interfering with the
remaining p53 wild type allele is required for protein stabilization (Suppl. Fig. S4B, C).
Interestingly, in 1 of 12 TgK18GT121tg/+/p53R172H/+ and 2 of 19 TgK18GT121tg/+/Brca1fl/fl/
p53R172H/+ mice with stage III or IV SEOC (Table 1), tumor sections revealed small foci
containing carcinoma cells with strong nuclear P53 expression suggesting spontaneous
protein stabilization (Suppl. Fig. S4B). Microdissection and sequence analysis confirmed the
loss of the p53 wildtype allele in tumor foci with increased nuclear P53 expression (Suppl.
Fig. S4D).
Taken together, these data suggest that RB-TS and p53 cooperate in the development of
metastatic SEOC. While only RB-TS inactivation is sufficient to initiate tumorigenesis, the
mutation/loss of both p53 alleles is required for the metastatic phenotype (stage IV disease).
Gene expression analysis of mouse ovarian tumors comfirms similarity to human SEOC
To determine whether TgK18GT121, p53, Brca1/2 driven tumors resemble human SEOC at
the molecular level, we performed global gene expression analysis on 27 ovarian carcinomas
and 3 pooled normal OSE samples (Supplementary Materials and Methods). Principle
component analysis (PCA) and unsupervised hierarchical clustering revealed that the
profiles of tumor samples were clearly distinct from normal OSE (Suppl. Fig. S5A). There
was no obvious subclustering based on Brca1 or Brca2 status at the global gene expression
level (Suppl. Fig. S5B) indicating that the majority of transcriptional changes are due to RB-
TS and p53 pathway perturbation. Sample-level-enrichment-based pathway ranking
(SLEPR) analysis (36) using Biocarta terms identified commonly altered pathways in
tumors compared to normal samples (Fig. 5A). As expected, RB, p53, DNA damage
signaling and repair pathway alterations were significantly changed in the majority of tumor
samples (Fig. 5A, Suppl. Fig. S5C). To determine whether these changes reflect networks
frequently disturbed in human high grade SEOC, TCGA curated pathways (6) were
compiled and reproduced using mouse orthologous genes. As in the majority of human
samples, the FOXM1 transcription factor network and its proliferation-related target genes
were consistantly overexpressed in the murine tumors (Suppl. Fig S5C).
The comparison of four histological types of human ovarian cancer (serous, endometrioid,
mucinous and clear cell) (10) with murine carcinoma samples revealed overlap of the
murine and human SEOC samples in the space of the three top principal components
relative to samples of other subtypes, indicating the strong similarity between these
expression profiles (Fig. 5B). Additionally, cluster analysis of merged mouse and human
data using classifier gene sets showed that mouse samples represent all 4 subgroups of
human SEOC originally derived from the TCGA study (6): differentiated (40%, 11/27),
immunoreactive (30%, 8/27), proliferative (15%, 4/27) and mesenchymal (15%, 4/27) (Fig.
5C) and are genetically distinct from diffuse malignant peritoneal mesotheliomas (Fig. 5D,
Suppl. Fig. S5D) (37).
Metabolic changes in blood from mouse SEOC resemble changes seen in human ovarian
cancer
To determine whether these mouse models can be utilized for biomarker discovery, we
performed metabolomic profiling on blood from 15 controls and 15 compound mutants with
either Brca1 or Brca2 deletion (Supplementary Materials and Methods) at three time points:
prior to intrabursal injection (T0), after onset of disease in compound mutants (T1: 12-20
weeks pi), and at termination of the experiment (T2: 24-45 weeks pi) (Fig. 6A). At 12 to 20
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weeks pi the OSE lesions in mice ranged from hyperplasia to early carcinoma (Stage IA),
which had further progressed to advanced disease stages at the terminal time point
(Supplementary Materials and Methods). Wild type mice had no significant changes in the
OSE at any time point. Representative MRI scans of the ovaries are depicted in Fig. 6B.
A total of 318 named biochemicals were identified comprising all major biochemical
groups. Two-way ANOVA identified biochemicals that had a significant main effect (p <
0.05) for either genotype or time, with the greatest changes occurring at the terminal time
point (Suppl. Fig. S6). Several metabolomic changes in tumor bearing animals overlap with
previous findings obtained from tissue of human patients with metastatic ovarian cancer
(38). These included increases in 2-hydroxybutyryate, three-hydroxybutyrate, citrate, α-
tocopherol and short chain acyl carnitines as well as a decrease in taurine (Fig. 6C).
In addition, blood of animals bearing metastatic ovarian cancer contained decreased
citrulline and increased spermidine and putrescine. The systemic redirection of ornithine
from the urea cycle to polyamine biosynthesis was expected to result in a significant
nitrogen stress to the animal and additional metabolites support this assertion. Specifically,
the TCA cycle associated amino acids aspartate and glutamate were both increased in the
blood of animals with metastatic ovarian cancer with aspartate increasing dramatically.
Besides its role in the urea cycle, aspartate serves as the predominant backbone of
pyrimidines in their de novo biosynthesis. The increased blood aspartate occurred
simultaneously with increased abundance of many pyrimidine pathway metabolites,
including orotate, uridine, thymidine and 2′-deoxycytidine (Fig. 6D, E). Several of the
metabolites revealed temporal changes during disease progression (Fig. 6F) indicating that
these mouse models provide a useful platform for the identification of candidate biomarkers
for earlier detection and/or for monitoring treatment response.
Discussion
Here we report highly penetrant GEM models for epithelial ovarian cancer. By interfering
with various combinations of RB, p53 and/or Brca protein functions, we dissected the
relative contribution of these pathways to the development of stage IV disease. As in
humans, mice developed peritoneal carcinomatosis, ascites and distant metastases. The
histological morphology and immunophenotypical expression of markers, such as CA125,
WT1, ER, PR mimics human SEOC. Additionally, transcriptional and metabolomic
profiling confirmed that Rb, p53, Brca1/2-triple mutant tumors align with human SEOC and
represent all 4 subclasses.
Previous studies showed that concomitant inactivation of Brca1 and p53 or Rb1 and p53 in
mouse OSE cells can give rise to advanced ovarian carcinomas with serous histology (11,
14, 16). While one study showed that intrabursal inactivation of Brca1 alone resulted in an
increase in the number of preneoplastic changes in the OSE 240 days pi (39), in our models
neither deletion/mutation of p53, Brca1 or Brca2 alone nor the combination thereof was
sufficient to cause any significant histological changes in the surface epithelium, which is
consistent with other reports (11, 13, 15, 16).
These data demonstrate that, of Brca1/2, p53 and RB pathway perturbation, only the latter
was sufficient to acutely initiate disease. The fact that Rb deletion by itself did not result in
histopathological abnormalities in previous studies (11, 13) implies that RB family members
compensate for the loss of pRB. Indeed, loss of p130 in addition to Rb deficiency previously
resulted in the acceleration of tumorigenesis in mouse models of lung adenocarcinoma and
small cell lung cancer (40, 41). While we do not propose that impaired Rb-pathway function
is the only possible initiating event, the present study (along with the high frequency of Rb
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pathway aberrations in human SEOC) suggests that this is a common initiation, while
impaired Brca1 or Brca2 and p53 facilitate SEOC progression.
The approach of targeting RB-TS inactivation specifically to epithelial cells via CK18
transcriptional regulation enabled us to minimize the appearance of ectopic tumors such as
lymphomas and sarcomas. Lymphatic, mesenchymal and smooth muscle cells can be
transformed more readily than epithelial cells, as seen in previous studies where conditional
inactivation of Brca1, p53 and Rb by intrabursal injection of Adeno-Cre resulted in the
development of leiomyosarcomas due to transformation of smooth muscle cells in the
ovarian bursa adjacent to the surface epithelium (13).
Mortality in SEOC patients is frequently due to the effects of disseminated abdominal
disease on vital organs such as the gastrointestinal tract, and is secondary to distant
metastasis. The latter may be present at the time of diagnosis (stage IV disease) or can arise
following relapse. The GEM models described here not only recapitulate intraperitoneal
spreading from a primary ovarian tumor but also the most common sites of distant
metastases found in humans: pleura, lung and liver (27). Human ovarian tumors harboring
mutations in both p53 alleles were more likely associated with high grade SEOC, lymph
node metastasis and the development of distant metastasis (42). In agreement with these
data, the progression to stage III/IV SEOC pathology in the GEM models was dependent on
biallelic mutation/inactivation of p53. While there was no obvious difference between
complete loss or stabilization of mutant p53, future studies will explore whether any
difference in ethiology or response to therapy results from these two mechanisms.
The combination of Brca1 inactivation with an initiation event did not appear to drive
progression beyond stage I disease (non-invasive carcinoma). However, in combination with
p53 aberration Brca1 inactivation may increase the incidence of disease. These findings are
consistent with studies of Brca1, Brca2, and Li-Fraumeni families (43), showing that
mutation carriers are predisposed to cancers, but the statistics of onset imply the need for
stochastic initiating event(s). Future studies examining global genome and expression
profiles of Brca wildtype and mutant SEOC may indicate potential differences. In addition,
these tumors may respond differently to therapeutic agents. The models described here can
be used to develop cell lines and allograft models for evaluating drug potency relative to
Brca mutation status.
Although the exact cellular origin(s) of SEOC in humans is unclear, the emerging
hypothesis is that the fallopian tube is the likely source (44, 45). This idea is based largely
on early tubal lesions detected after prophylactic surgery in BRCA1 mutation carriers
(46-49). Because progression cannot be followed in these cases, it is difficult to conclude
that the lesions detected will give rise to SEOC. It is also possible that SEOC can arise from
multiple sites. Experimental transformation of human OSE as well as human epithelial cells
derived from the fallopian tube gave rise to high grade SEOC, respectively (32, 50). In this
study, we showed that GEM-SEOC can initiate in the OSE, based on assessment of a
significant number of induced mice at distinct times during progression in which disease
was limited to the ovary. In some other cases, viral leakage to the adjacent oviduct (fallopian
tube), was detected, but resulted in distinct pathology. Though the vast majority of human
SEOC express Pax8, which is consistent with their origin in fallopian tube epithelium, it has
not yet been shown to be a defining/requisite feature of these tumors. The preponderance of
the remaining evidence (morphology, other IHC markers, and gene expression profiling)
suggests that the murine tumors in our study resemble SEOC rather than mesotheliomas.
Many of the existing murine ovarian carcinoma models have been derived by transformation
of OSE (10, 11, 16). While one study showed similarity to human endometrioid ovarian
cancer based on transcriptional profiling (10), SEOC-like mouse models were characterized
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mainly based on histopathological features (11, 16). The status of Pax8 expression in these
models was not described. Future experiments limiting induction to tubal epithelia in these
models will facilitate addressing the cell or origin paradigm.
In conclusion, we have developed GEM models of SEOC with several key
histopathological, immunophenotypical and genetic features of human SEOC. These models
will serve as a foundation for future preclinical research.
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Cre-mediated induction of genetic events in OSE cells by intra-bursal Adeno-Cre injection.
A, Scheme depicting the targeting strategy. B, Expression of GFP, T121 antigen and CK18
in serial sections from ovaries of a TgK18GT121tg/+ mouse 3 months pi. GFP expression (a,
brown, arrows) and lack of T121 expression (c) in uninduced OSE. Occasional GFP staining
(b, arrows) and T121 expression (d, brown, arrows) in the induced OSE. Note that the OSE
is hyperplastic with increased numbers of tightly packed columnar cells. IHC staining for
CK18 (brown) depicts epithelial cells (e, f, arrows). C, CIS (*) in the induced OSE of a
TgK18GT121tg/+ mouse 6 months pi (a). IHC confirming the expression of T121 (b; brown).
SEOC with minimal invasion into underlying ovary in a TgK18GT121tg/+ mouse 24 months
pi (c). Note unaffected fimbriae and oviduct. Higher magnification of SEOC (d). Scale bars
in B represent 50 μm and in C 100 μm.
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Histopathological contribution of single and compound genetic events in the transformation
of OSE. A, RB-TS pathway inactivation in TgK18GT121tg/+ mice is sufficient to initiate
surface epithelial proliferation and early SEOC. B, Individual or combined inactivation of
Brca1, Brca2 and/or p53 are insufficient to cause ovarian epithelial tumorigenesis. C,
Combination of TgK18GT121 and p53 alleles causes SEOC. D, Disease staging in mice with
compound induction of RB-TS, p53 and Brca1 or Brca2. N: normal, HP: hyperplasia, CIS:
carcinoma in situ. E, Statistical evaluation of disease progression based on histology score
(HP=0.25, CIS=0.5, Stage IA=1.0, IB=1.5, IIA=2.0, IIB=2.5, IIIA=3.0, IIIB=3.5, IV=4).
Mice removed from study before the age of 3 months were not included in the statistical
analysis. Bars depict group mean histology score with error bars representing standard error
of the means. One way-ANOVA with Bonferroni’s Multiple Comparison post-test was used
to test for significant differences between genotypes. F, Explanation of the histopathological
staging system used. The classification was adopted from FIGO used in human ovarian
carcinomas.
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Perturbation of Rb-TS, p53 and/or Brca1/2 in the OSE induces metastatic serous epithelial
ovarian carcinomas. A, MRI of a TgK18GT121tg/+/Brca1fl/fl/p53R172H/fl mouse showing a
large ovarian tumor on the induced ovary. B, Abdominal distention and presence of ascites
in the same mouse. C, Ovarian tumor and normal non-injected ovary of the same mouse 190
days pi. D, Early SEOC originating from the OSE (50×). Note intact bursa and unaffected
oviduct. Range of different histological SEOC features: E, Papillary histology of SEOC
shown in D; F, poorly differentiated glandular and microcystic histology; G, micropapillary/
filigree; H, papillary and I, solid tumor histology. J, Intraperitoneal spreading
(carcinomatosis) on serosal surface of liver (arrow). K, Pleural metastasis (arrow), note
alveolar spaces in underlying lung parenchyma (*). L, Liver micrometastases showing the
presence of papillary carcinoma within distended hepatic sinusoids (arrow and arrowhead).
Scale bar in C represents 1 cm, in D to L 100μm.
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Immunophenotype of SEOC arising from the mouse ovarian surface and oviduct epithelium,
as well as abdominal carcinomatosis and human peritoneal mesothelioma. Normal mouse
OSE (a, g, m s), carcinomas arising from the OSE (b, h, n, t), abdominal carcinomatosis (c,
i, o, u), normal oviduct epithelium (d, j, p, v), adenocarcinomas arising from the oviduct (e,
k, q, w) and human DMPM (f, l, r, x). Rare expression of CK5 indictated by arrow in w.
Scale bars represent 200μm.
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Gene expression patterns and molecular subtypes of mouse SEOC mirror high grade human
SEOC. A, Top ranked pathways enriched in tumors versus normals based on SLEPR
analysis using Biocarta terms with inclusion of manually curated TCGA pathways (*). The
enrichment scores were directly used to create the heatmap in ranked order (higher ranked
genes at the top based on the permutated p-values of each pathway). Red, enriched
significantly; black, no significant enrichment based on enrichment score of individual
sample less than 1.3 (p>0.05) or Gene Hits less than 2. B, PCA of merged microarray data
from mouse SEOC and four histological subtypes of human ovarian cancer [GSE6008;
(10)]. C, Microarray data from mouse SEOC were merged and clustered together with
human SEOC using the TCGA classifier genes (6). Genes in the heatmap were ordered
based on their predictive classes of Differentiated, Immunoreactive, Mesenchymal and
Proliferative tumor subtypes. The rows depict human (black) or mouse (grey) samples. The
data in its original log2 intensity were scaled for purpose of display in heatmap: mean as 0
and standard deviation as 1 for each gene across all samples. D, PCA plot of the top two
principal components for mouse tumors and a variety of subtypes of human ovarian
carcinomas in the subset of the merged human-mouse array dataset containing the available
human-mouse homologous genes out of 189-gene signature previously described to
distinguish DMPM from SEOC (11).
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Metabolomic profiling of blood during SEOC progression. A, Experimental design. B,
Representative MRI scans from mice 8, 20 and 27 weeks pi, respectively. Arrow indicates
the injected ovary, T indicates the ovarian tumor. Scale bar represents 1cm. C, Similar
changes in human ovarian cancer tissue (38) and murine whole blood metabolome (this
study). D, Integrative model of metabolomic changes observed in the blood of mice with
SEOC compared to their littermate controls. Metabolites whose abundance increased are
shown in red, decreased in green and unchanged or not detected in black. E, Boxplots
comparing the abundance distribution of select metabolites between animals with metastatic
ovarian cancer and their littermate (wt) controls at the terminal time points. F, Heat maps
depicting temporal metabolite changes in SEOC compared to WT mice. The colors display
each group mean level to the median for that compound, such that white represents the
median, saturated red represents a two-fold increase relative to and saturated blue is one-half
the median value.
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